XORTX Therapeutics (XRTX) Capital Expenditures (2022 - 2023)
XORTX Therapeutics (XRTX) posted Capital Expenditures of $8621.0 for Q4 2023, up 626.63% on a QoQ basis from -$1637.0 in Q2 2023, and down 74.19% year-over-year from $33402.8 in Q4 2022.
XORTX Therapeutics (XRTX) Capital Expenditures (2022 - 2023) Analysis & Trends
XORTX Therapeutics' Capital Expenditures history runs 2 years deep, the most recent figure standing at $8621.0 for Q4 2023.
- Quarterly Capital Expenditures fell 74.19% year-over-year to $8621.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $4311.0 (changed N/A YoY) and the FY2023 annual result came in at $4311.0, down 78.11% from the prior year.
- Capital Expenditures was $8621.0 for Q4 2023 at XORTX Therapeutics, up from -$1637.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $33402.8 in Q4 2022 and bottomed at -$2673.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | XORTX Therapeutics | 20.40 Mn | 20.40 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 8,621.00 |
| Dec 31, 2023 | 8,621.00 |
| Jun 30, 2023 | -1,637.00 |
| Jun 30, 2023 | -1,637.00 |
| Mar 31, 2023 | -2,673.00 |
| Mar 31, 2023 | -2,673.00 |
| Dec 31, 2022 | 33,402.85 |
| Dec 31, 2022 | 33,402.85 |
| Sep 30, 2022 | -444.71 |
| Sep 30, 2022 | -444.71 |